» Articles » PMID: 30632669

UNC5D, Suppressed by Promoter Hypermethylation, Inhibits Cell Metastasis by Activating Death-associated Protein Kinase 1 in Prostate Cancer

Overview
Journal Cancer Sci
Specialty Oncology
Date 2019 Jan 12
PMID 30632669
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) death primarily occurs due to metastasis of the cells, but little is known about the underlying molecular mechanisms. This study aimed to evaluate the expression of UNC5D, a newly identified tumor suppressor gene, analyze its epigenetic alterations, and elucidate its functional relevance to PCa metastasis. Meta-analysis of publicly available microarray datasets revealed that UNC5D expression was frequently downregulated in PCa tissues and inversely associated with PCa metastasis. These results were verified in clinical specimens by real-time PCR and immunohistochemistry assays. Through methylation analysis, the downregulated expression of UNC5D in PCa tissues and cell lines was found to be attributable to the hypermethylation of the promoter. A negative correlation was observed between methylation and UNC5D mRNA expression in PCa samples. The ectopic expression of UNC5D in PCa cells effectively reduced their ability to migrate and invade both in vitro and in vivo, and siRNA-mediated knockdown of UNC5D yielded consistent results. UNC5D can recruit and activate death-associated protein kinase 1, which remained to be essential for its metastatic suppressor function. In conclusion, these results suggested that UNC5D as a novel putative metastatic suppressor gene that is commonly down-regulated by hypermethylation in PCa.

Citing Articles

Molecular characterization analysis of PANoptosis-related genes in colorectal cancer based on bioinformatic analysis.

Zhang M, Li W, Zhao Y, Qi L, Xiao Y, Liu D PLoS One. 2024; 19(8):e0307651.

PMID: 39186800 PMC: 11346968. DOI: 10.1371/journal.pone.0307651.


Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review).

Jin C, Liao S, Lu G, Geng B, Ye Z, Xu J Mol Med Rep. 2024; 30(3).

PMID: 38994760 PMC: 11258599. DOI: 10.3892/mmr.2024.13286.


DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment.

Baluszek S, Kober P, Rusetska N, Wagrodzki M, Mandat T, Kunicki J Acta Neuropathol Commun. 2023; 11(1):113.

PMID: 37434245 PMC: 10337070. DOI: 10.1186/s40478-023-01610-0.


Research on Potential Network Markers and Signaling Pathways in Type 2 Diabetes Based on Conditional Cell-Specific Network.

Xie Y, Cui Z, Wang N, Li P Genes (Basel). 2022; 13(7).

PMID: 35885938 PMC: 9320152. DOI: 10.3390/genes13071155.


Promoter methylation-mediated repression of UNC5 receptors and the associated clinical significance in human colorectal cancer.

Dong D, Zhang R, Shao J, Zhang A, Wang Y, Zhou Y Clin Epigenetics. 2021; 13(1):225.

PMID: 34922605 PMC: 8684698. DOI: 10.1186/s13148-021-01211-5.


References
1.
Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang F, Villella J . Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer. 2003; 2:24. PMC: 156646. DOI: 10.1186/1476-4598-2-24. View

2.
Claus R, Hackanson B, Poetsch A, Zucknick M, Sonnet M, Blagitko-Dorfs N . Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer. 2011; 131(2):E138-42. PMC: 3463871. DOI: 10.1002/ijc.26429. View

3.
Yegnasubramanian S . Prostate cancer epigenetics and its clinical implications. Asian J Androl. 2016; 18(4):549-58. PMC: 4955178. DOI: 10.4103/1008-682X.179859. View

4.
Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

5.
Raffo A, Perlman H, Chen M, Day M, Streitman J, Buttyan R . Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995; 55(19):4438-45. View